The Evaluation of Diagnostic Role of Cardiac Troponin T (cTnT) in Newborns with Heart Defects

Agata Tarkowska and Wanda Furmaga-Jabłońska

Department of Neonate and Infant Pathology, Medical University of Lublin, 20095 Lublin, Poland

Correspondence should be addressed to Agata Tarkowska, a_tar@poczta.onet.pl

Received 28 October 2011; Accepted 30 November 2011

Aim of the Study. To evaluate diagnostic usefulness of cTnT in correlation with other markers of circulatory failure and myocardial damage in newborns with heart defects.

Patients and Methods. The study involved 83 newborns up to 46 weeks of postmenstrual age. The exclusion criteria were severe perinatal asphyxia and presence of severe noncardiac diseases. Patients were divided into 2 main groups: group I—54 patients with congenital heart defects (CHDs), and group II (control)—29 healthy neonates. All patients underwent detailed examination of circulatory system. Cardiac troponin T (cTnT) concentrations were evaluated by Roche CARDIAC T Quantitive test.

Results. Performed studies revealed that cTnT levels in newborns with heart pathology were significantly higher than in healthy ones. However, cTnT concentrations in patients with CHD did not correlate with clinical symptoms of heart failure, nor with echocardiographic markers of LV function. Type of heart defect did not influence cTnT levels as well. Only hemodynamic significance evaluated by echocardiography influenced the cTnT levels with statistical significance.

Conclusions. (1) Statistically significant differences in cTnT levels between newborns with heart defects and healthy subjects were shown. (2) CTnT levels in newborns with heart defects refer only to hemodynamic significance of the defect.

1. Introduction

Heart diseases leading to circulatory failure are a significant cause of morbidity and mortality in newborns [1]. Diagnosis of early stages heart failure in newborn is difficult because clinical symptoms are nonspecific. The diagnostic methods indicating cardiac damage are often not sufficient or, in many cases, cannot be used due to high technical requirements or their invasive nature [2]. It is necessary to look for noninvasive markers that would enable wider diagnosis of heart muscle damage and cardiac insufficiency risk in neonates.

Cardiac troponins are protein components of the troponin-tropomyosin complex in myocardium. Since troponins do not occur in extracellular space, their appearance in serum is sensitive and specific marker of myocardium damage [3]. Troponins appear in blood in 2 to 4 hours after insult, peak in about 12 h and then remain elevated for 7–10 days [3, 4].

Sensitivity of both cTnT and cTnI in the diagnosis of myocardial damage is clinically almost equal. They differ in intracellular compartments, biological half-life, and molecular weight [5]. There are also differences in the standardization and availability of commercial troponin kits. Absolute values of gained results are often incomparable, however, diagnostic features of particular methods are similar [6].

Cardiac troponins (cTn) are biochemical markers of myocardial injury with unquestionable significance in diagnostic strategy in adults [3, 7–11]. However, their role in diagnostics in neonates has not been fully explored yet. Cardiac troponins have not been used routinely in neonates because of insufficient data confirming their clinical utility in this age group. Studies conducted in other groups confirm
the usefulness of troponins in clinical situations that lead to cardiomyocytes injury, including cardiac inflammatory diseases [2, 4, 5, 12–14]. In literature, the following applications of cTn in pediatrics are mentioned: acute myocarditis, heart arrhythmias, perinatal asphyxia in newborns, perioperative myocardial injury in patients operated for congenital heart diseases, drug-induced cardiotoxicity, and cardiac transplantation [4, 5, 14].

2. The Aim of the Study

Was to evaluate the diagnostic usefulness of cTnT measurements in correlation with other markers of circulatory failure and myocardial damage in newborns with congenital heart defects.

3. Patients and Methods

The study involved 83 newborns up to 46 weeks of postmenstrual age. The gestational age of studied newborns was 25–42 weeks; mean: 38 weeks. Chronological age (in days from the date of birth) was 6–135 days, mean: 21 days. Postmenstrual age was 34–46 weeks, mean: 41 weeks. Birth weight of studied newborns was 585–5400 g, mean: 3137 g. The exclusion criteria were severe perinatal asphyxia (Apgar scale ≤ 4 points in 1st and 5th minute) and patients with signs of severe noncardiac diseases.

All patients underwent detailed subjective and physical examination. In patients with abnormalities in circulatory system echocardiography and electrocardiographic tests were performed. On the basis of performed examination, patients were divided into 2 main groups: group I—54 patients with congenital heart defects (CHDs), and group II (control)—29 healthy neonates up to 46 weeks of postmenstrual age. Newborns with CHD were divided into following subgroups: group Ia—with simple shunts and group Ib—with combined heart defects (Table 1). Patients in group I were also divided according to hemodynamic significance of the heart defect evaluated in echocardiography. Hemodynamic significance was evaluated on the base of echocardiographic parameters such as right ventricle and/or right atrium enlargement, accelerated blood flow in main pulmonary artery (MPA), and extension of MPA, presence of tricuspid regurgitation, extension of pulmonary veins. The particular criteria of hemodynamic significance depended on the type of heart defect. The following subgroups were stated: group IIa—with hemodynamic significant defect and group IIb—without hemodynamic significance. The comparison of clinical variables between particular groups is presented in Tables 4 and 5.

Each newborn with cardiac abnormality had the following examinations performed: echocardiography with left ventricle ejection fraction (EF LV) evaluation, chest X-ray, and blood pressure measurement. All patients were also evaluated with Ross’s heart failure in infants classification [15] and with Reithmann’s pediatric heart failure score [16]. Basic laboratory tests were performed in each newborn. The study protocol was approved by the Ethics Committee of Medical University of Lublin.

Troponin T levels were evaluated in 150 µL of whole blood by Roche CARDIAC T Quantitative test (third generation; Roche Diagnostics). The Roche CARDIAC T quantitative test includes two monoclonal antibodies specific for cardiac troponin T. Measuring range of the test is 0.03 to 2 ng/mL. The results are not influenced by hyperbilirubinemia (bilirubin <20 mg/dL), hemolysis nor lipemia (triglycerides <440 mg/dL). Blood samples were collected into standardized heparinized tubes. The obtained results, after checking the normality of distribution, were statistically analyzed by the use of appropriate test with Statistica 9.0 packet. Right-handed asymmetry of certain distributions was eliminated by the use of logarithmic transformation. Dependency analysis was performed based on Pearson’s linear correlation coefficient (r) or Spearman’s (R) rank correlation test and t-test significance of the correlation coefficient in the population. The results were concerned as statistically significant when P < 0.05.

4. Results

Performed studies revealed that cTnT levels in newborns with heart pathology were significantly higher than in healthy ones (P = 0.035, Figure 1, Table 2). However, cTnT concentrations in patients with CHD did not correlate with clinical symptoms of heart failure evaluated with Ross’s scale (R = 0.095 and P = 0.493) as well as with Reithmann’s classification (R = 0.076, P = 0.493). Cardiac TnT concentrations also did not correlate with echocardiographic markers of LV function, nor with the type of heart defect. The obtained results revealed that only hemodynamic significance of heart defect evaluated by echocardiography influenced the cTnT levels with statistical significance (P = 0.048, Table 3).

5. Discussion

Cardiac troponins are highly specific cardiac markers, extremely sensitive, and valuable in diagnostics of myocardial necrosis [17, 18]. Sobki et al. [19] in their paper demonstrated that troponins are very highly sensitive and specific for myocardial injury. Other studies showed that troponin elevations may occur in different cardiac pathologies, not only in ischemic heart disease [18]. According to studies conducted on adult patients, increased oxygen demand in myocardium and the increase of cardiac troponins serum concentration occur in clinical situations like: arrhythmias (atrial fibrillation, supraventricular tachycardia, etc.), in chronic and acute heart failure, or in myocarditis [17]. The accurate mechanisms responsible for the elevation of troponin serum concentration in diseases other than acute coronary syndromes remain in the course of research [18]. According to data from literature, elevated cTn concentrations in cardiac insufficiency are connected with the decrease of left ventricular ejection fraction and correlate with the severity of symptoms and with worse prognosis [17]. While
Table 1: Characteristic of heart defects in group I patients.

| Division of heart defects Group I (N = 54) | Type of defect          | Number of patients |
|------------------------------------------|-------------------------|--------------------|
| Simple shunts (Group Ia) N = 16          | ASD + VSD               | 10                 |
|                                          | ASD + VSD + PDA         | 2                  |
|                                          | ASD + PDA               | 2                  |
|                                          | PDA                     | 1                  |
|                                          | ASD                     | 1                  |
|                                          | CAVC                    | 5                  |
|                                          | FT4                     | 2                  |
| Hemodynamically significant defects (Group II) N = 29 | PS + ASD               | 1                  |
| Combined heart defects (Group Ib) N = 13 | CoA + ASD               | 1                  |
|                                          | TA                      | 1                  |
|                                          | L-TGA + VSD + PS        | 1                  |
|                                          | DORV + ASD              | 1                  |
|                                          | SA + PS + ASD + PDA     | 1                  |
| Defects without hemodynamic significance (Group II) N = 25 | ASD                    | 11                 |
| Simple shunts (Group Ia) N = 24          | ASD + PDA               | 7                  |
|                                          | ASD + VSD               | 4                  |
| Combined heart defects (Group Ib) N = 1  | PS + ASD                | 1                  |

N: number of patients
ASD: atrial septum defect
VSD: ventricular septum defect
PDA: persistent ductus arteriosus
CoA: aortic coarctation
PS: pulmonary stenosis
DORV: double outlet left ventricle
TA: truncus arteriosus
TGA: transposition of great arteries
SA: aortic stenosis

Table 2: Number of patients with particular cTnT concentration ranges in studied groups.

| cTnT (ng/mL) | Newborns with heart defects group I (N = 54) | Control group II (N = 29) | Statistical significance |
|--------------|---------------------------------------------|---------------------------|--------------------------|
| <0.03        | 20                                          | 6                         |                          |
| 0.03–0.1     | 24                                          | 22                        | P = 0.035                |
| 0.1–2.0      | 10                                          | 1                         |                          |

N: number of patients.

these biomarkers were widely studied in adult patients, with structurally normal hearts, it is unknown if the results correlate with heart failure in newborns and infants with congenital heart defects. Typically, cardiac insufficiency in adults is usually connected with coronary disease, whereas in children heart failure is rather complication of structural abnormalities or primary myocardial dysfunction [20].

Shah et al. [20] in their study made an attempt to evaluate whether serum cTnI concentrations in children with functionally single-chamber heart may be used as biomarker of heart failure. The study included 29 children at the age of 1 month to 7 years, with functionally single-chamber heart. No differences in cTnI concentrations were found between patients with functionally one ventricle and heart failure and those without cardiac insufficiency. In most patients, cTnI concentrations were undetectable.

Similarly, on the basis of the results obtained in our study, no difference was stated between serum cTnT concentrations and clinical exponents of heart failure. The obtained results did not show correlation with clinical symptoms of heart failure evaluated with Ross’s heart failure in infants classification, nor with Reithmann’s pediatric heart failure score. Heart failure is more frequently observed in neonates, especially in preterms [21]. In the available literature, there was no study evaluating correlation between clinical heart failure symptoms and cardiac troponins concentrations in newborns with congenital heart defects. The obtained results, similar as data from literature concerning older children with CHD, confirm that in opposite to adults, cardiac troponins concentration in pediatric patients does not correlate with the severity of clinical heart failure symptoms. Most probably, this follows different etiopathogenesis of heart failure in children and adults. Although, Muñiz [22] in his paper presented a case report of patient at the age of 9 weeks with combined congenital heart defect and chronic
The noncompliance in our results and results of the cited study is due to differences between the groups of studied patients. On the other hand, SF is not a reliable indicator of left ventricle systolic function in newborns, because of the typical adaptation period high blood pressure in right ventricle, which influences septum movements [25]. In case of congenital structural heart defects, this discrepancy may be even more strongly expressed.

Structural heart defects are the most often inborn malformations diagnosed in the first year of life [21]. Studies conducted in adults with heart defects showed that mean cTnT concentration was higher in patients with aortic valve pathology compared with control group [26]. Also elevated pulmonary blood pressure might be connected with increased cTnI serum concentrations [26]. In available literature, there is a very small number of studies evaluating troponin concentrations in pediatric patients with heart defects. In order to determine the influence of congenital or acquired heart defects on cardiac troponin serum concentrations, Hirsch et al. [27] evaluated cTnI levels in two groups of children. Group A was represented by pediatric patients without diagnosed heart disease and stable patients with known congenital or acquired cardiac abnormalities. Group B was created from patients admitted to Intensive Care Unit: with normal ECHO results, with abnormal ECHO results, or after chest injury. The mentioned authors stated that cTnI levels are generally not elevated in children with stable heart disease or in children with systemic diseases.

On the basis of our studies, it was found that cTnT serum concentration is statistically significantly higher in newborns with CHD compared to patients from the control group. In available literature, it is difficult to find studies concerning troponin concentrations in neonatal patients with heart defects. One of the papers [23] showed that cTnT concentrations in newborns with persistently ductus arteriosus (PDA) significantly correlated with the arterial duct diameter, the shunt velocity, and end diastolic volume in descending aorta. The authors concluded that cTnT may be a useful marker of PDA significance and reaction to treatment, as it correlates with echocardiographic PDA markers. Elevated cTnT concentration may reflect the potential myocardial damage caused by the presence of PDA. Stealing of oxygenated blood by arterial duct can influence the coronary flow, and potentially lead to ischemia [23].

In another research, conducted by EL-Khuffash et al. [24] on group of preterm newborns with PDA, cTnT evaluation, and ECHO examination were performed in the first day of life. Significant negative correlation was found between cTnT and echocardiographic markers of left ventricle (LV), including SF LV. Correlation between PDA diameter and cTnT was not confirmed. This was the only study as yet in which correlation between cTnT and EF LV in newborns was found. According to the authors, the above results may have practical application in indirect evaluation of myocardial function in newborns when echocardiography is not available. In the same paper, it was shown that cTnT did not depend on cardiac volume load.

In available literature, there were no other studies found concerning cardiac troponin concentrations in CHD in newborns with heart defect in their 12th hour of life [24]. The authors were correlated with echocardiographic measurements in studied groups.
newborns before cardiosurgical treatment. In our previous study, cTnI concentrations were evaluated in 41 newborns at the age of 7–28 days with CHD [28]. No differences were found in cTnI concentration in studied patients depending on type of heart defect (simple or combined). However, elevated cTnI levels were found in newborns with pulmonary hypertension (HP), secondary to structural heart defect compared to group without HP and the difference was close to statistical significance. Results of the present study does not confirm this observation, as no significant correlation was observed between cTnI concentrations in dependence of heart defect hemodynamic significance.

The results of our study confirmed that although cTnT concentrations are significantly higher in newborns with CHD compared to healthy ones, however, no significant difference was found depending on the type of the defect. In newborns with isolated left-to-right shunt defects, no significant correlation was observed between cTnT concentration and shunt velocity evaluated by echocardiography. Also, no significant correlation was found between cTnT concentration and the diameter of septal defect or PDA. However, the obtained results showed significant correlation between cTnT concentration and hemodynamic significance of heart defect evaluated on the basis of echocardiographic evaluation. Heart defects more hemodynamically significant carry greater risk of heart failure development and necessity to start appropriate treatment as soon as possible. The correlation between cTnT concentration and hemodynamic significance of CHD creates potential possibility for above biomarker to be used for early detection of newborns with significant heart defects, who need urgent cardiology consultation.

### 6. Conclusions

1. Statistically significant differences in cTnT levels between newborns with heart defects and healthy subjects were shown.
2. Cardiac TnT concentrations in newborns with CHD does not correlate with clinical signs of heart failure nor with echocardiographic markers of LV function.
3. Cardiac TnT concentrations in newborns with CHD does not depend on the type of the defect.
4. The statistically significant correlation was found between cTnT concentration and hemodynamic significance of CHD in examined newborns.

### References

[1] W. Kawalec and K. Kubicka, “Choroby układu krazenia,” in *Pediatria*, K. Kubicka and W. Kawalec, Eds., pp. 270–339, Wyd. III. PZWL, Warszawa, Poland, 2008.
[2] J. Soongsawang, K. Durongpisitkul, A. Nana et al., “Cardiac troponin T: a marker in the diagnosis of acute myocarditis in children,” *Pediatric Cardiology*, vol. 26, no. 1, pp. 45–49, 2005.
[3] B. Solnica, ”[Cardiac troponins],” *Medycyna Praktyczna*, vol. 10, pp. 133–136, 2004.
[4] E. Braunwald, A. S. Fauci, and D. L. Kasper, *Harrison’s Principles of Internal Medicine*, McGraw-Hill, New York, NY, USA, 15th edition, 2001.
[5] M. Adamcová, “Troponins in children and neonates,” *Acta Paediatrica*, vol. 92, no. 12, pp. 1373–1375, 2003.
[6] T. S. Mir, S. Maroohn, S. Lärer, M. Eisel, O. Grollmus, and J. Weil, ”Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure,” *Pediatrics*, vol. 110, no. 6, p. e76, 2002.
[7] T. B. Horwich, J. Patel, W. R. MacLellan, and G. C. Fonarow, “Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure,” *Circulation*, vol. 108, no. 7, pp. 833–838, 2003.
[8] A. A. Mohammed and J. L. Januzzi, ”Natriuretic peptides in the diagnosis and management of acute heart failure,” *Heart Failure Clinics*, vol. 5, no. 4, pp. 489–500, 2009.
[9] R. Sakhuja, S. Green, E. M. Oestreicher et al., “Amino-terminal pro-brain natriuretic peptide, brain natriuretic peptide, and troponin T for prediction of mortality in acute heart failure,” Clinical Chemistry, vol. 53, no. 3, pp. 412–420, 2007.

[10] R. R. Baliga and J. B. Young, “Do biomarkers deserve high marks?” Heart Failure Clinics, vol. 5, no. 4, pp. ix–xii, 2009.

[11] R. Latini, S. Masson, I. S. Anand et al., “Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure,” Circulation, vol. 116, no. 11, pp. 1242–1249, 2007.

[12] E. Masłowska, “[Troponin T(TnT) in children with heart diseases],” Pediatria Polska, vol. 6, supplement, p. 21, 1999.

[13] J. Soongswang, K. Durongpisitkul, S. Ratanarapee et al., “Cardiac troponin T: its role in the diagnosis of clinically suspected acute myocarditis and chronic dilated cardiomyopathy in children,” Pediatric Cardiology, vol. 23, no. 5, pp. 531–535, 2002.

[14] S. Kaplan, “Biochemical markers of myocardial injury in children,” Circulation, vol. 96, no. 8, pp. 2496–2497, 1997.

[15] R. D. Ross, “Grading the graders of congestive heart failure in children,” Journal of Pediatrics, vol. 138, no. 5, pp. 618–620, 2001.

[16] C. Reithmann, D. Reber, R. Kozlik-Feldmann et al., “A post-receptor defect of adenylyl cyclase in severely failing myocardium from children with congenital heart disease,” European Journal of Pharmacology, vol. 330, no. 1, pp. 79–86, 1997.

[17] Y. Agzew, “Elevated serum cardiac troponin in non-acute coronary syndrome,” Clinical Cardiology, vol. 32, no. 1, pp. 15–20, 2009.

[18] L. De Gennaro, N. D. Brunetti, A. Cuculo et al., “Increased troponin levels in nonischemic cardiac conditions and non-cardiac diseases,” Journal of Interventional Cardiology, vol. 21, no. 2, pp. 129–139, 2008.

[19] S. H. Sobki, S. M. Saadeddin, and M. A. Habbab, “Cardiac markers used in the detection of myocardial injury,” Saudi Medical Journal, vol. 21, no. 9, pp. 843–846, 2000.

[20] A. Shah, A. M. Feraco, C. Harmon, T. Tacy, J. R. Fineman, and H. S. Bernstein, “Usefulness of various plasma biomarkers for diagnosis of heart failure in children with single ventricle physiology,” American Journal of Cardiology, vol. 104, no. 9, pp. 1280–1284, 2009.

[21] M. Correale, L. Nunno, R. Ieva et al., “Troponin in newborns and pediatric patients,” Cardiovascular and Hematological Agents in Medicinal Chemistry, vol. 7, no. 4, pp. 270–278, 2009.

[22] A. E. Muñiz, “Elevated cardiac troponin I in a 9-week-old infant,” Pediatric Emergency Care, vol. 20, no. 10, pp. 674–676, 2004.

[23] A. F. El-Khuffash and E. J. Molloy, “Serum troponin in neonatal intensive care,” Neonatology, vol. 94, no. 1, pp. 1–7, 2008.

[24] A. El-Khuffash, P. G. Davis, K. Walsh, and E. J. Molloy, “Cardiac troponin T and N-terminal-pro-B type natriuretic peptide reflect myocardial function in preterm infants,” Journal of Perinatology, vol. 28, no. 7, pp. 482–486, 2008.

[25] A. El-Khuffash and E. J. Molloy, “Are B-type natriuretic peptide (BNP) and N-terminal-pro-BNP useful in neonates?” Archives of Disease in Childhood: Fetal and Neonatal Edition, vol. 92, no. 4, pp. F320–F324, 2007.

[26] J. P. L. Nunes, J. M. M. Garcia, R. M. B. Farinha et al., “Cardiac troponin I in aortic valve disease,” International Journal of Cardiology, vol. 89, no. 2–3, pp. 281–285, 2003.

[27] R. Hirsch, Y. Landt, S. Porter et al., “Cardiac troponin I in pediatrics: normal values and potential use in the assessment of cardiac injury,” Journal of Pediatrics, vol. 130, no. 6, pp. 872–877, 1997.

[28] A. Tarkowska and W. Furmaga-Jabłońska, “Troponin I (TnI) serum concentration in newborns with arrhythmias and heart defects,” Pediatria Polska, vol. 85, no. 6, pp. 549–554, 2010.